ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

DOW JONES NEWSWIRES Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations. The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline. Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion. Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion. Operating margin rose to 36.4% from 34.9%. Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion. The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million. Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading. -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
05/23/201514:03:02Healthcare Investment Opportunities for the Long Term
05/22/201521:04:50Amgen Ends Psoriasis-Drug Partnership With AstraZeneca -- Update
05/22/201517:40:50Amgen Ends Psoriasis-Drug Partnership With AstraZeneca
05/22/201516:22:00Amgen to terminate participation in co-development and commercialization...
05/22/201507:31:00Amgen Receives Positive CHMP Opinion For Use Of Repatha⢠(Evolocumab) F...
05/20/201512:15:10What Is the S&P 500 Index?
05/19/201511:36:02Forget MannKind Stock's Price: Here's What You Need to Focus...
05/18/201516:00:00Amgen Appoints Jonathan P. Graham Senior Vice President, General...
05/17/201509:05:022 Stocks With Jaw-Dropping Growth Potential
05/15/201506:06:00Current Report Filing (8-k)
05/15/201504:00:00Amgen Presents First Phase 2 Data For AMG 334 In The Prevention...
05/14/201517:58:00Amgen Announces Voting Results of Annual Meeting of Stockholders
05/13/201517:00:00Amgen Data At ASCO 2015 Highlight Oncology Pipeline And Portfolio
05/13/201507:17:02The "Best of Breed" Dividend Stocks
05/12/201516:06:00Amgen's Breakaway From Cancer® Announces Winners Of Its Nationwide...
05/12/201510:26:025 Largest Markets for Pharmaceuticals
05/11/201516:58:04Statement of Changes in Beneficial Ownership (4)
05/11/201516:05:00Amgen To Present AMG 334 Data At 17th Congress of the International...
05/11/201511:40:11Court Blocks Novartis Copy of Amgen Cancer-Care Drug
05/08/201517:01:13Regeneron Earnings Shine, but All Eyes Are on the Pipeline

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad